Evidence map›Paper›PMID 26186636›Full record

ArticlePloS one2015

Tannic Acid Inhibits Hepatitis C Virus Entry into Huh7.5 Cells.

Shuanghu Liu, Ren Chen, Curt H Hagedorn

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Antifungal activity of tannic acid against Candida spp. and its mechanism of action.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  3. Willow (Frontiers in microbiology · 2023
    Article
  4. Microorganisms · 2022
    Article
  5. Article
  6. Article
  7. Antiviral Properties of Polyphenols from Plants.Foods (Basel, Switzerland) · 2021
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Entry inhibitors: New advances in HCV treatment.Emerging microbes & infections · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shuanghu LiuDepartment of Medicinal Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT, United States of America; Department of Medicine, University of Utah, Salt Lake City, UT, United States of America.
Ren ChenDepartment of Medicine, University of Utah, Salt Lake City, UT, United States of America.
Curt H HagedornDepartment of Medicine, University of Utah, Salt Lake City, UT, United States of America; Department of Medicine, University of Arkansas for Medical Sciences Little Rock, AR, United States of America; Program in Genetics, University of Arkansas for Medical Sciences Little Rock, AR, United States of America; The Central Arkansas Veterans Healthcare System, Little Rock, AR, United States of America.
University of Utah · US

Funding

Molecular Phenotype of Polyps in Serrated Polyposis SyndromeR21CA176130 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI HAGEDORN, CURT H. · 2013 to 2014
$350k
Sentinel Pol II RNAs for Measuring RNA Integrity in BiospecimensR21CA148068 · NCI · UNIVERSITY OF UTAH · PI HAGEDORN, CURT H. · 2011 to 2012
$343k
NCI NIH HHS CA148068NCI NIH HHS CA176130NCI NIH HHS R21 CA148068NCI NIH HHS R21 CA176130
6 · The paper itself

Abstract

Chronic infection with the hepatitis C virus (HCV) is a cause of cirrhosis and hepatocellular carcinoma worldwide. Although antiviral therapy has dramatically improved recently, a number of patients remain untreated and some do not clear infection with treatment. Viral entry is an essential step in initiating and maintaining chronic HCV infections. One dramatic example of this is the nearly 100% infection of newly transplanted livers in patients with chronic hepatitis C. HCV entry inhibitors could play a critical role in preventing HCV infection of newly transplanted livers. Tannic acid, a polymer of gallic acid and glucose molecules, is a plant-derived polyphenol that defends some plants from insects and microbial infections. It has been shown to have a variety of biological effects, including antiviral activity, and is used as a flavoring agent in foods and beverages. In this study, we demonstrate that tannic acid is a potent inhibitor of HCV entry into Huh7.5 cells at low concentrations (IC50 5.8 μM). It also blocks cell-to-cell spread in infectious HCV cell cultures, but does not inhibit HCV replication following infection. Moreover, experimental results indicate that tannic acid inhibits an early step of viral entry, such as the docking of HCV at the cell surface. Gallic acid, tannic acid's structural component, did not show any anti-HCV activity including inhibition of HCV entry or replication at concentrations up to 25 μM. It is possible the tannin structure is related on the effect on HCV inhibition. Tannic acid, which is widely distributed in plants and foods, has HCV antiviral activity in cell culture at low micromolar concentrations, may provide a relative inexpensive adjuvant to direct-acting HCV antivirals and warrants future investigation.

Indexed as

Antiviral AgentsCell Line, TumorCell SurvivalGene ExpressionGenes, ReporterHepacivirusHepatocytesHumansLuciferasesRepliconTanninsVirus InternalizationVirus ReplicationAntiviral AgentsLuciferasesTannins

Identifiers

PMID26186636
PMCPMC4505941
OpenAlexW906765051

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.